Navigation Links
Potential gene therapy for Sickle cell disease
Date:7/2/2013

Sickle cell disease (SCD) is an autosomal recessive disorder caused by mutations in hemoglobin (HBB) that deform red blood cells. A small number of patients have been successfully treated with allogeneic hematopoietic stem cell (HSC) transplantation; however, there are several drawbacks and complications associated with this procedure, including graft vs. host disease and long-term immune suppression. Many of complications could potentially be avoided by the use of autologous HSC transplant, which uses patient cells that have been treated genetically modified to replace defective hemoglobin. In this issue of the Journal of Clinical Investigation, Zulema Romero and colleagues investigated the utility of a genetic vector encoding a human hemoglobin gene engineered to impede sickle hemoglobin and prevent the sickling of red blood cells. The vector was used to efficiently transduce bone marrow cells from SCD patients and the transduced cells were successfully transplanted into immunocompromised mice, suggesting that this method could potentially be used to treat SCD.


'/>"/>

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related biology technology :

1. Dual-acting class of antimalarial compounds discovered with potential to prevent and treat malaria
2. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
3. Carnegie Mellon study reveals potential of manganese in neutralizing deadly Shiga toxin
4. GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
5. Carbon capture and storage -- new research from UKERC shows tough road ahead to realize potential
6. Researchers Find Potential Link Between Drinking Alcohol And Breast Cancer
7. Golden potential for gold thin films
8. Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
9. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
10. Welcome to BIO-Poland Explore Our Potential
11. AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 05, 2016 , ... This composition patent, U.S. Patent No. ... The composition claims are not limited to any particular process to make or ... carbon fibers, graphene, and other materials. A continuation application, U.S. Patent App. ...
(Date:12/5/2016)... , Dec. 5, 2016  Renova™ Therapeutics, ... congestive heart failure and other chronic diseases, announced ... the company as Chief Financial Officer (CFO), effective ... with 20 years of experience in financial management ... biotech and software companies. Most recently, Ms. Bovenizer ...
(Date:12/5/2016)... , December 5, 2016 The ... with almost $108 billion of revenue and some $890 ... were spent on global biopharmaceuticals, and this figure is ... Stock-Callers.com has lined up these four equities for assessment: ... Pharmaceuticals Inc. (NASDAQ: ACAD ), Acorda Therapeutics ...
(Date:12/2/2016)... ... ... In anticipation of AxioMed’s exclusive cleanroom manufacturing facility in ... Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski will meet ... to discuss the benefits of a viscoelastic disc. AxioMed received CE mark in ...
Breaking Biology Technology:
(Date:11/30/2016)... SAN FRANCISCO and WARSAW, Poland , Nov. 30, 2016 ... sleeping. It is one of the most crucial aspects of recovery so we need ... host of serious health risks, including heart problems, high blood pressure, stroke, diabetes, and ... family and friends sleep and find a Christmas present that could help them to ... ...
(Date:11/29/2016)... Lithuania , Nov. 29, 2016 /PRNewswire/ ... biometric identification and object recognition technologies, today ... (SDK) for fingerprint recognition solutions that run ... a fingerprint template using less than 128KB ... in compact devices that have limited on-board ...
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
Breaking Biology News(10 mins):